Akebia Therapeutics, Inc.
AKBANASDAQHealthcare● Active
$0.92
$-0.01(-1.44%)
Market Cap$247280223
P/E Ratio—
52W High$4.079
52W Low$0.875
Akebia Therapeutics, Inc. (AKBA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AKBA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.03
Est. -$0.01 · -200.0%
Revenue
$0.05B
Est. $0.05B · +3.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
AKBA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.03 | — | — | — | $0.05B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.01 | -$0.03 | -200.0% | $0.05B | $0.05B | +3.6% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.03 | -$0.05 | -66.7% | $0.06B | $0.05B | +25.0% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.06 | $0.00 | +103.3% | $0.06B | $0.05B | +21.5% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.02 | $0.00 | +104.5% | $0.06B | $0.05B | +30.4% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.03 | $0.03 | +200.0% | $0.06B | $0.05B | +12.9% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -$0.05 | -$0.10 | -100.0% | $0.05B | $0.04B | +24.3% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.05 | -$0.10 | -100.0% | $0.04B | $0.04B | -8.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.03
EPS Est.
-$0.01
EPS Surpr.
-200.0%
Revenue
$0.05B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$0.05
EPS Est.
-$0.03
EPS Surpr.
-66.7%
Revenue
$0.06B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
$0.00
EPS Est.
-$0.06
EPS Surpr.
+103.3%
Revenue
$0.06B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.00
EPS Est.
-$0.02
EPS Surpr.
+104.5%
Revenue
$0.06B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.03
EPS Surpr.
+200.0%
Revenue
$0.06B
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$0.10
EPS Est.
-$0.05
EPS Surpr.
-100.0%
Revenue
$0.05B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.10
EPS Est.
-$0.05
EPS Surpr.
-100.0%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.09 | $-0.09 | $-0.07 | 1 |
| Q3 FY2027 | $-0.09 | $-0.09 | $-0.07 | 1 |
| Q2 FY2027 | $-0.09 | $-0.09 | $-0.07 | 1 |
| Q1 FY2027 | $-0.09 | $-0.09 | $-0.07 | 1 |
| Q4 FY2026 | $-0.03 | $-0.02 | $-0.02 | 1 |
| Q3 FY2026 | $-0.06 | $-0.05 | $-0.03 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.1B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -200.0% | $1.48 | $1.18 | -20.27% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -66.7% | $1.21 | $1.32 | +9.09% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +103.3% | $2.04 | $1.67 | -18.14% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +104.5% | $3.79 | $3.01 | -20.58% |
| ▲ Q2 FY2025 | May 8, 2025 | +200.0% | $2.46 | $2.62 | +6.50% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -100.0% | $1.93 | $1.69 | -12.44% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -100.0% | $2.00 | $1.87 | -6.50% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +33.3% | $1.11 | $1.19 | +7.21% |
Q2 FY2026-20.27%
Report Date
May 7, 2026
EPS Beat/Miss
-200.0%
Price Before
$1.48
Price After
$1.18
Q1 FY2026+9.09%
Report Date
Feb 26, 2026
EPS Beat/Miss
-66.7%
Price Before
$1.21
Price After
$1.32
Q4 FY2025-18.14%
Report Date
Nov 10, 2025
EPS Beat/Miss
+103.3%
Price Before
$2.04
Price After
$1.67
Q3 FY2025-20.58%
Report Date
Aug 7, 2025
EPS Beat/Miss
+104.5%
Price Before
$3.79
Price After
$3.01
Q2 FY2025+6.50%
Report Date
May 8, 2025
EPS Beat/Miss
+200.0%
Price Before
$2.46
Price After
$2.62
Q1 FY2025-12.44%
Report Date
Mar 13, 2025
EPS Beat/Miss
-100.0%
Price Before
$1.93
Price After
$1.69
Q4 FY2024-6.50%
Report Date
Nov 7, 2024
EPS Beat/Miss
-100.0%
Price Before
$2.00
Price After
$1.87
Q3 FY2024+7.21%
Report Date
Aug 8, 2024
EPS Beat/Miss
+33.3%
Price Before
$1.11
Price After
$1.19
Avg Beat Reaction-6.25%
Avg Miss Reaction-7.53%
Beat Rate4 / 8 quarters
Largest Move-20.58% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AKBA ends December
Akebia Therapeutics, Inc. (AKBA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.03 — missing the analyst consensus of $-0.01 by -200.0%. The next AKBA earnings date is expected around September 1, 2026.
Each quarter, investors track AKBA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AKBA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AKBA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AKBA earnings · 5 questionsAkebia Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. AKBA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AKBA historically reports after market close (AMC).
AKBA earnings datewhen is AKBA earningsAKBA next earnings datewhen does AKBA report earningsAKBA earnings calendar
▸ Source: FMP · Akebia Therapeutics, Inc. SEC filings · US GAAP · Akebia Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026